Concepedia

Checkpoint Abrogation

Checkpoint Abrogation is a regulatory mechanism in cell cycle biology characterized by the premature inactivation or bypass of mitotic checkpoints, leading to the disruption of proper chromosome segregation and often resulting in mitotic catastrophe.

88

Publications

6.6K

Citations

506

Authors

175

Institutions

Publications per year

2017–2026

11

Parents

Publications

88

Excess MCM proteins protect human cells from replicative stress by licensing backup origins of replication

Arkaitz Ibarra, Étienne Schwob, Juan Méndez · Proceedings of the National Academy of Sciences · 2008 · 502 citations · Full text

, , +17

UCN-01: a Potent Abrogator of G2 Checkpoint Function in Cancer Cells With Disrupted p53

Qizhi Wang, Songqing Fan, Alan Eastman et al. · JNCI Journal of the National Cancer Institute · 1996 · 447 citations · Full text

, , +17

G2 checkpoint abrogators as anticancer drugs

Takumi Kawabe · Molecular Cancer Therapeutics · 2004 · 383 citations · Full text

, , +17

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2 Checkpoint and Inhibition of Homologous Recombinational DNA Repair

Meredith A. Morgan, Leslie A. Parsels, Lili Zhao et al. · Cancer Research · 2010 · 299 citations · Full text

, , +13

Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

Yuli Wang, Jun Li, Robert N. Booher et al. · PubMed · 2001 · 217 citations

, , +17

1–5 of 88

Authors

506

  1. TS
    Theodore S. Lawrence

    University of Michigan, United States

    6 publications · 730 citations

    6

    h-index

  2. SZ
    Sonya Zabludoff

    AstraZeneca (United States), United States

    4 publications · 544 citations

    4

    h-index

  3. JM
    Jonathan Maybaum

    University of Michigan, United States

    4 publications · 460 citations

    4

    h-index

  4. TK
    Takumi Kawabe

    Dana-Farber Cancer Institute, United States

    4 publications · 446 citations

    4

    h-index

  5. JD
    Joshua D. Parsels

    University of Michigan, United States

    4 publications · 460 citations

    4

    h-index

1–5 of 506

Institutions

175

  1. University of Michigan

    Ann Arbor, United States

    5 h-index

    37 publications

    5.7K citations

  2. National Cancer Institute

    Bethesda, United States

    4 h-index

    19 publications

    3.6K citations

  3. Abbott Fund

    Chicago, United States

    4 h-index

    19 publications

    1.1K citations

  4. Howard Hughes Medical Institute

    Chevy Chase, United States

    4 h-index

    8 publications

    988 citations

  5. Cancer Research UK

    London, United Kingdom

    3 h-index

    20 publications

    1.7K citations

  6. Shandong University

    Jinan, China

    3 h-index

    17 publications

    260 citations

  7. University of California San Diego

    San Diego, United States

    3 h-index

    11 publications

    1.2K citations

  8. Inserm

    Paris, France

    3 h-index

    9 publications

    439 citations

1–8 of 175

Venues

  1. Molecular Cancer Therapeutics

    MCT · 13 publications · 1.2K citations

    12

    h-index

  2. Cell Cycle

    7 publications · 296 citations

    7

    h-index

  3. Cancer Research

    6 publications · 636 citations

    6

    h-index

  4. PubMed

    Repository · 4 publications · 420 citations

    4

    h-index

  5. BMC Cancer

    3 publications · 126 citations

    3

    h-index

1–5